Lilly’s New Anti-Amyloid Play Hinges On Tau Bet

Redesigned Phase III Trial May Confirm Phase II Donanemab Results

 
• By Mandy Jackson
  
Poker chips on red background
Lilly's bet on donanemab depends on tau levels and tau burden reductions • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D